STE

STE

STERIS plc (Ireland) Ordinary Shares

$242.230+0.000 (0.000%)

Echtzeitkurs

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$242.230

Hoch

$242.230

Tief

$242.230

Volumen

0.47M

Unternehmensfundamentaldaten

Handelsstatistiken

KI-Analysebericht

Zuletzt aktualisiert: 20. Mai 2025
KI-generiertDatenquelle: Yahoo Finance, Bloomberg, SEC

STE: STERIS plc (Ireland) Ordinary Shares - What's Happening and What to Watch

Stock Symbol: STE Generate Date: 2025-05-20 21:14:12

Let's break down what's been going on with STERIS lately, looking at the news buzz, how the stock price has moved, and what some predictions are saying.

Recent News Buzz: Feeling Pretty Good

The news around STERIS has been leaning positive lately. We've seen a few different investment firms – Morgan Stanley, JMP Securities, and Stephens & Co. – weighing in. The big takeaway? Two of them actually raised their price targets for the stock. Morgan Stanley bumped theirs up to $260, and JMP Securities went even higher to $280. Stephens & Co. kept their target steady at $250, but they still have an "Overweight" rating, which is generally a positive sign.

On top of that, the company recently announced its financial results for the full fiscal year 2025. The headline here is that revenue from continuing operations grew by 6%. That's solid growth. They also declared a quarterly dividend of $0.57 per share, which is always a nice bit of news for shareholders.

So, the overall vibe from recent news? Analysts seem optimistic, and the company reported decent financial performance and is returning cash to shareholders. That's a good mix.

Price Check: A Recent Climb

Looking at the stock's movement over the past month or two, it's had a bit of a journey. For a while, it was trading in a range, mostly between $220 and $230 through March and into April. There was a dip in early April, but it recovered.

Then, around mid-May, things changed. Right after the earnings announcement (May 14th), the price saw a significant jump. It went from the $220s and low $230s and shot up, hitting a 52-week high of $252.79 on May 19th. The current price is right around that peak, closing at $250.47 on May 20th.

The AI prediction for today suggested a tiny dip (-0.21%), which seems to have played out slightly with the close just below the recent high. For the next couple of days, the AI sees a small bounce (0.55%) followed by a larger dip (-2.11%). This suggests some potential choppiness right after the big run-up.

Outlook & Ideas: Riding the Wave, But Be Mindful

Putting the pieces together, the recent news is definitely supportive, with analysts raising targets and the company showing revenue growth. The stock price has clearly reacted positively to this, making a strong move upwards in the last week.

Given the positive analyst sentiment and the recent price surge, the near-term picture appears to lean positive, suggesting the momentum is currently with the buyers. However, the stock is now trading right at its 52-week high, and the AI predicts a potential dip in the next couple of days, especially the day after tomorrow.

  • Potential Entry Consideration: Since the price has run up so much already and the AI hints at a near-term dip, jumping in right at the peak might feel risky. If you were considering getting in, one approach could be to watch if the predicted dip happens. The recommendation data mentions potential entry points around $251.29 and $252.25, and support near $251.91. The current price is right in this zone. So, if you're comfortable with the current level given the positive news, it's around the area some models see as relevant. Alternatively, waiting for a pullback towards a recent support level (maybe in the low $240s, where it was before the big jump) could be another strategy, though there's no guarantee it will dip that far.
  • Potential Exit/Stop-Loss Consideration: For managing risk, especially after a big move, thinking about exit points is smart. The recommendation data suggests a potential take profit level around $257.66. This is above the current price and below the highest analyst target, offering some room to climb if the positive trend continues. On the downside, a stop-loss level around $241.48 is suggested. This is below the recent surge's starting point and could help limit potential losses if the stock reverses sharply.

Company Context: Healthcare Backbone

Remember, STERIS is a major player in the Medical Devices and Healthcare sector. They provide critical infection prevention products and services to hospitals and other healthcare providers. This means their business is tied to the healthcare industry's stability and growth. The recent revenue increase fits within this context, showing demand for their offerings. The analyst focus and price targets reflect expectations for this specific type of healthcare support business.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Ähnliche Nachrichten

Analyst Upgrades

Jefferies Initiates Coverage On Steris with Hold Rating, Announces Price Target of $263

Jefferies analyst David Windley initiates coverage on Steris with a Hold rating and announces Price Target of $263.

Mehr anzeigen
Jefferies Initiates Coverage On Steris with Hold Rating, Announces Price Target of $263
Analyst Upgrades

Morgan Stanley Maintains Equal-Weight on Steris, Raises Price Target to $260

Morgan Stanley analyst Patrick Wood maintains Steris with a Equal-Weight and raises the price target from $240 to $260.

Mehr anzeigen
Morgan Stanley Maintains Equal-Weight on Steris, Raises Price Target to $260
Analyst Upgrades

JMP Securities Maintains Market Outperform on Steris, Raises Price Target to $280

JMP Securities analyst David Turkaly maintains Steris with a Market Outperform and raises the price target from $265 to $280.

Mehr anzeigen
JMP Securities Maintains Market Outperform on Steris, Raises Price Target to $280
Analyst Upgrades

Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target

Stephens & Co. analyst Steven Etoch reiterates Steris with a Overweight and maintains $250 price target.

Mehr anzeigen
Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target
GlobeNewswire

STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted

Mehr anzeigen
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

KI-VorhersageBeta

KI-Empfehlung

Bärisch

Aktualisiert am: 12. Juni 2025, 18:44

BärischNeutralBullisch

60.9% Konfidenz

Risiko & Handel

Risikostufe3/5
Mittleres Risiko
Geeignet für
Konservativ
Handelsleitfaden

Einstiegspunkt

$240.35

Gewinnmitnahme

$245.55

Stop-Loss

$232.96

Schlüsselfaktoren

DMI zeigt bärischen Trend (ADX:16.8, +DI:4.6, -DI:5.3), was zur Vorsicht mahnt
Aktueller Preis ist extrem nah am Unterstützungsniveau ($240.71), was auf eine starke Kaufgelegenheit hindeutet
Handelsvolumen ist 8.9x Durchschnitt (6,935), was auf extrem starken Kaufdruck hindeutet
MACD -0.2767 liegt über der Signallinie -0.3009, was auf einen bullischen Crossover hindeutet

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.